Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients

Table 1 Characteristics of cancer patients from the clinic database selected for data analysis: number of subjects, sex, age range, weight range, and average ascorbate concentrations before and immediately after the first 15 gram IVC infusion

Cancer type	N	M/F	Age (years)	Weight (lbs)	Ascorbic acid, post (mM)	Ascorbic acid, pre (mM)	Ascorbic acid, minimum pre (mM)
Bladder	10	8/2	32–80	160–192	5.00	0.078	0.045
Brain	12	3/9	26–66	126–137	6.73	0.051	0.045
Breast	105	1/133	38–72	104–190	6.57	0.076	0.023
Breast, metastatic	28	0/28	36–64	93–250	5.45	0.060	0.017
Chronic Lymphocytic Leukemia	15	8/7	50–67	125–213	5.52	0.059	0.023
Colon	34	23/11	50–78	110–280	5.46	0.063	0.017
Colon, metastatic	26	16/10	50–69	106–200	6.23	0.062	0.028
Esophagus	5	5/0	48–77	ND	5.99	0.080	0.068
Esophagus, metastatic	5	5/0	50–63	114–280	6.11	0.055	0.011
Liver	8	5/3	14–58	99–157	5.78	0.057	0.034
Liver, metastatic	7	3/4	50–69	85–160	5.90	0.052	0.028
Lung	43	25/18	49–75	104–290	5.81	0.051	0.011
Lung, metastatic	20	10/10	25–78	107–178	5.07	0.060	0.017
lymphoma (non-Hodgkin’s)	6	1/5	40–65	120–159	5.13	0.077	0.063
Melanoma	11	3/8	26–72	130–207	5.26	0.068	0.063
Ovarian	36	0/36	31–76	108–217	6.59	0.058	0.017
Pancreas	16	11/5	58–80	149–200	5.65	0.051	0.028
Pancreas, metastatic	11	7/4	65–80	132–174	5.13	0.068	0.045
Prostate	64	64/0	59–89	147–250	5.61	0.063	0.017
Prostate, metastatic	7	7/0	59–88	150–225	4.64	0.059	0.023
Renal	17	10/7	51–76	72–229	6.08	0.055	0.040
Renal, metastatic	13	7/6	39–68	ND	5.89	0.063	0.040
Sarcoma	7	5/2	21–75	90–163	4.98	0.045	0.023
Skin	6	6/0	54–76	175–211	5.54	0.051	0.028
Stomach	5	4/1	33–77	ND	4.75	0.051	0.028
Throat	7	4/3	34–80	ND	5.40	0.063	0.034
Thymus	7	4/3	48–73	48–73	5.39	0.068	0.051
Uterus	7	0/7	52–70	99–173	6.62	0.068	0.051

ISSN: 1479-5876